Synthesis and biological studies of nociceptin derivatives containing the DTPA chelating group for further labeling with therapeutic radionuclides.
Nociceptin is an endogenous anti-opiate heptadecapeptide primarily interacting with the nociceptin (NOP) receptor. This neuropeptide-receptor system is involved in pain regulation, tolerance to and dependence on opiates as well as many other physiological and pathophysiological events. The role and mechanisms of nociceptin in pathological conditions is not clearly known yet. In an attempt to have a radiopharmaceutical labeled either with 99mTc or (111)In, we incorporated diethylenetriaminepentaacetic acid (DTPA) as chelator into the structure of [Arg14,Lys15]nociceptin(1-17)-NH2 at the epsilon-amino group of Lys15. Such a radiopeptide may be useful in imaging for diagnostical purposes. Preparation of the peptide ligands was carried out by solid phase synthesis. Two peptides containing DTPA were obtained and purified. The products were [Arg14,Lys(DTPA)15]nociceptin(1-17)-NH2 and its cross-linked dimer on the basis of mass spectrometric analysis. In (115)In3+ binding experiments the conjugates exhibited preserved indium ion chelating properties, indicating the potential use of radiolabeled DTPA-nociceptin derivatives as radiopharmaceutical. Biological properties of these compounds were studied in rat brain membrane preparations by radioligand binding, functional biochemical [35S]GTPgammaS binding assays and mouse vas deferens (MVD) bioassay. Besides the similar in vitro binding characteristics to nociceptin receptor, both of the DTPA-chelated compounds were more potent and efficient than nociceptin in functional biochemical and mouse vas deferens bioassays. Our further aim is to radiolabel these compounds in order to get a radiopharmaceutical which can be used diagnostically.
Ligeti
Melinda
M
Research Group of Peptide Chemistry, Eötvös University and Hungarian Academy of Sciences, Budapest, Hungary.
Gündüz
Ozge
O
Magyar
Anna
A
Kató
Erzsébet
E
Rónai
András Z
AZ
Vita
Claudio
C
Varga
Imre
I
Hudecz
Ferenc
F
Tóth
Géza
G
Borsodi
Anna
A
Benyhe
Sándor
S
D000818:Animals; D001681:Biological Assay; D002614:Chelating Agents / Q000737:chemistry*; D019281:Dimerization; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D007205:Indium Radioisotopes / Q000737:chemistry; D007553:Isotope Labeling; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D018847:Opioid Peptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D004369:Pentetic Acid / Q000737:chemistry; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology*; D019275:Radiopharmaceuticals / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D011957:Receptors, Opioid / Q000819:agonists* / Q000737:chemistry; D013667:Technetium / Q000737:chemistry; D014649:Vas Deferens / Q000187:drug effects; D000094942:Nociceptin Receptor; D000097629:Nociceptin
D002614:Chelating Agents; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D007205:Indium Radioisotopes; D018847:Opioid Peptides; D004369:Pentetic Acid; D010446:Peptide Fragments; D019275:Radiopharmaceuticals; D011957:Receptors, Opioid; D013667:Technetium; D000094942:Nociceptin Receptor; D000097629:Nociceptin; C504515:nociceptin (1-17)amide, Arg(14)-Lys(DTPA)(15)-